Clinical Trials Logo

Adrenocortical Carcinoma clinical trials

View clinical trials related to Adrenocortical Carcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06333314 Not yet recruiting - Soft Tissue Sarcoma Clinical Trials

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

Pan-MSI-ACSE
Start date: May 2024
Phase: Phase 2
Study type: Interventional

The goal of this open-label randomized, multicenter, comparative phase II trial is to evaluate the efficacy of the immunotherapy, dostarlimab, as first-line treatment for deficient mismatch repair (dMMR)/microsatellite instability (MSI) non-resectable metastatic or locally advanced non-colorectal and non-endometrial cancers compared to the standard of care chemotherapy. Adult patients (aged ≥18 years) with histologically confirmed dMMR/MSI duodenum and small bowel adenocarcinoma, gastric and oeso-gastric junction (OGJ) adenocarcinoma with combined positive score (CPS)<5, pancreatic adenocarcinoma, ampulla of vater adenocarcinoma, adrenocortical carcinoma, carcinoma of unknown primary site, neuroendocrine carcinoma (Grade3) all primary, and soft tissue sarcoma (except Gastro-Intestinal Stromal Tumor) will be included in this study. They will be randomized and treated with either dostarlimab (experimental arm A), or chemotherapy (control arm B). Patients with documented disease progression following the first line chemotherapy (Arm B) may be eligible for crossover to be treated with dostarlimab, with the same schedule as arm A.

NCT ID: NCT06279442 Not yet recruiting - Clinical trials for Carcinoma, Adrenocortical Recurrent

Adrenal Project: Clinical and Epidemiological Characterization of Adrenocortical Carcinoma in a Brazilian Cohort

Start date: June 2024
Phase:
Study type: Observational

This is a retrospective observational cohort study. The clinical, pathological and treatment data of participants identified with adrenocortical carcinoma from the year 2000 onwards will be evaluated. Participants recruited for this study will be identified at the participating sites.

NCT ID: NCT05839886 Not yet recruiting - Clinical trials for Adrenocortical Carcinoma

The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma

MEET
Start date: May 1, 2023
Phase:
Study type: Observational

This work will evaluate the adverse effects of mitotane treatment in patients treated for ACC with mitotane therapy. All of the individuals were treated at Ruijin Hospital between May 2023 and May 2024.